Storch H, Dellas T, Bellmann H
Z Exp Chir. 1978;11(2):128-33.
The widespread intravenous application of hyaluronidase rises questions for its potential immunogenicity, formation of humoral antibodies, and danger of anaphylaxis. In experiments on 21 rabbits and 40 rats, the authors searched for precipitating antibodies after subcutaneous, intramuscular, and intravenous application of hyaluronidase in doses equivalent to the human. Intravenous and intramuscular shots of 150 to 75 000 IU of Hylase were applied in order to test anaphylaxis. By all proving procedures antibodies against Hylase were found. The formation of antibodies occurred earlier and in higher concentrations after subcutaneous and intramuscular application. The antibodies belonged to the IgG group. One third of the animals showed anaphylactic responses at doses which were 13 to 630 times as high. 26 per cent of human patients developed antibodies after application of Hylase. No anaphylactic reactions were observed in 17 patients with antibodies when intravenous application of hyaluronidase was continued. In the dosage used in the man anaphylactic response is obviously rare though it is possible.
透明质酸酶在静脉内的广泛应用引发了关于其潜在免疫原性、体液抗体形成以及过敏反应风险的问题。在对21只兔子和40只大鼠进行的实验中，作者在皮下、肌肉内和静脉内注射相当于人类剂量的透明质酸酶后，寻找沉淀抗体。为了测试过敏反应，静脉内和肌肉内注射了150至75000国际单位的透明质酸酶。通过所有检测程序，均发现了针对透明质酸酶的抗体。皮下和肌肉内注射后，抗体形成更早且浓度更高。这些抗体属于IgG组。三分之一的动物在剂量高出13至630倍时出现过敏反应。26%的人类患者在应用透明质酸酶后产生了抗体。在17名有抗体的患者中，继续静脉注射透明质酸酶时未观察到过敏反应。在人类使用的剂量下，过敏反应虽然有可能发生，但显然很少见。
